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 The enterohepatic circulation of bile acids is maintained by the active transport of bile acids across 
the apical and basolateral plasma membrane domains of intestinal enterocytes and hepatocytes. 
Uptake of bile acids from sinusoidal blood into hepatocytes is mediated by the Na+-taurocholate 
cotransporting polypeptide NTCP (SLC10A1), as well as by sodium-independent uptake transporters 
from the family of organic anion transporting polypeptides (OATPs). OATP1B1 and OATP1B3 are 
expressed almost exclusively in hepatocytes, whereas OATP2B1 and OATP1A2 exhibit a wide 
tissue distribution (1). Uptake of bile acids from the intestinal lumen into enterocytes is mediated by 
the apical sodium-dependent bile acid transporter ASBT (SLC10A2). At the basolateral membrane, 
bile acids are effluxed into portal blood by the heterodimeric organic solute transporters alpha and 
beta (OSTα / OSTβ). 
 
The expression level of bile acid transporters is regulated in part by direct or indirect effects of 
bile acids on the transcription of the corresponding genes. The transcriptional effects of bile acids 
are mediated largely by the nuclear bile acid receptor FXR (NR1H4 gene in humans). The 
endogenous ligands of FXR include bile acids, with CDCA being the more potent ligand than CA (2-
4), as well as the oxysterol 22(R)-hydroxycholesterol (5) and androsterone (6). Naturally occurring 
exogenous ligands include stigmasterol, a soy lipid-derived phytosterol that appears to function as 
an antagonist of FXR activity, thereby possibly contributing to the cholestasis associated with 
neonatal parenteral nutrition (7), as well as cafestol, a diterpenic compound found in coffee beans 
and in unfiltered coffee that functions as an FXR agonist (8). Synthetic FXR ligands include GW4064 
and the semi-synthetic bile acid derivative 6-ethyl chenodeoxycholic acid (9). In accordance with its 
function as the bile acid receptor, FXR is most abundantly expressed in the tissues commonly 
exposed to bile acids: liver, intestine, and kidneys. The preferred DNA-binding sequence for FXR 
within its target promoters is the so-called "inverted repeat-1" motif (IR-1, inverted hexameric repeat 
separated by one base pair) (10), to which FXR binds as a heterodimer with another nuclear 
receptor, namely the retinoid X receptor (RXR). 
 
Bile acid transporters that are directly transactivated by FXR include OATP1B3 (SLCO1B3) at 
the basolateral membrane of hepatocytes (11), and the bile salt efflux pump BSEP (ABCB11), the 
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multidrug resistance protein MRP2 (ABCC2) and the multidrug resistance gene product MDR3 
(ABCB4) at the canalicular membrane (12). In the intestine, the heterodimeric transporter OSTα / 
OSTβ is activated by FXR (13). FXR can also lead to inhibition of bile acid transporter gene 
expression, usually this involves activation of the transcriptional repressor protein short heterodimer 
partner (SHP). Target genes of FXR mediated repression include NTCP (SLC10A1) and OATP1B1 
(SLCO1B1) in hepatocytes, and  ASBT (SLC10A2) in the intestine. 
 
In the case of NTCP and ASBT, the mechanism of bile acid / FXR mediated gene suppression have 
been recently elucidated. Both genes, SLC10A1 and SLC10A2, are activated by the glucocorticoid 
receptor, GR (14, 15). Bile acid activated FXR induces the transcriptional repressor SHP, which 
negatively interacts with the GR, thereby reducing GR-mediated activation of gene transcription. The 
negative interaction of SHP with nuclear receptors has also been found in the context of the 
hepatocyte nuclear factor HNF-4α. HNF-4α directly binds to and activates the promoter regions of 
the genes coding for the organic cation transporter OCT1 (SLC22A1) and the organic anion 
transporter OAT2 (SLC22A7) (16). Bile acid-induced SHP inhibits the activation of the reporter-
linked hOCT1 and hOAT2 promoters by HNF-4α (17, 18) and thus decreases endogenous 
expression of OCT1 and OAT2. Another gene that is regulated by HNF-4α is the hepatocyte nuclear 
factor HNF-1α. HNF-1α binds to and activates the transcription of the SLCO1B1 gene, thereby 
maintaining a high level of OATP1B1 expression in the liver (19). Bile acid activated SHP reduces 
HNF-4α regulated HNF-1α expression, thereby indirectly also reducing OATP1B1 expression (20). 
Since OATP1B1 transports not only bile acids, but also a variety of drugs, decreased OATP1B1 
expression in conditions associated with elevated intracellular bile acid levels is bound to affect the 
hepatic uptake and thus the pharmacokinetics of OATP1B1 substrates such as simvastatin (21). 
 
In an analogous manner to the SLCO1B3 gene, expression of the OSTα / OSTβ heterodimeric bile 
acid efflux system is induced by bile acids through direct binding of FXR-RXR heterodimers to the 
two human OST promoters (13, 22). In addition to established cell lines, both OSTα and OSTβ gene 
expression can be induced by bile acids in short-term tissue culture of human ileal biopsies. Further 
physiological evidence in support of the induction of OST gene expression by bile acids is provided 
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by a study showing that both mRNA and protein levels of OSTα and OSTβ are increased in 
cholestatic liver tissue of patients suffering from primary biliary cirrhosis (23). Furthermore, reduced 
expression of FXR correlates with decreased expression of OSTα / OSTβ in the ileum of female 
non-obese gallstone patients (24). 
 
The Familial Intrahepatic Cholestasis-1 (FIC1) protein, encoded by the ATP8B1 gene, is expressed 
at the liver canalicular membrane and at the apical membrane of enterocytes, in addition to many 
other tissues (25). FIC1 acts as an aminophospholipid flippase, translocating phosphatidylserine 
from the outer leaflet of the lipid bilayer of the plasma membranes. Genetic variants in the ATP8B1 
gene have been associated with familial intrahepatic cholestasis, characterized by low γ-
glutamyltranspeptidase plasma levels. In PFIC1 patients, decreased hepatic and intestinal mRNA 
levels of FXR and of genes transactivated by FXR have been found (26, 27). FIC1 may influence the 
expression and/or function of FXR, perhaps contributing to the pathogenesis of the liver disease. In 
a recent report, it was shown that whereas the wild-type FIC1 was capable of potent activation of the 
BSEP promoter, the PFIC1-associated FIC1 variants were inactive, and the BRIC1-associated FIC1 
variants activated the BSEP promoter to only a moderate degree (28). The authors hypothesized 
that the wild-type FIC1 protein induces nuclear localization of FXR through stimulation of a 
phosphorylation cascade targeting FXR, and that FIC1-related disease may be caused by the 
compromised ability of the associated FIC1 variants to influence FXR localization and function. 
 
In summary, bile acids are capable of regulating the expression of transporters that mediate the 
enterohepatic circulation of both bile acids and drugs via complex feedforward and feedback 
mechanisms. A key signalling molecule in these transcriptional circuits is the nuclear bile acid 
receptor FXR, which binds to defined response elements and thus activates transcription of target 
genes in the presence of FXR ligands, or represses gene transcription through the action of the 
repressor SHP, which negatively interacts with key transcriptional activators such as HNF-4α or the 
glucocorticoid receptor. 
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